SCHEMBL18244698

SCHEMBL18244698

CC(C)(C)[Si](OCCCCCCCC/C=C\CO)(c1ccccc1)c1ccccc1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMYD2 Q9NRG4 2/20 0.33
CYP3A4 P08684 1/20 0.33
HTT P42858 1/20 0.33
SMN1; SMN2 Q16637 1/20 0.33
ACLY P53396 1/20 0.33
PPARG P37231 1/20 0.33
PPARA Q07869 1/20 0.33
HDAC3 O15379 1/20 0.32
HDAC4 P56524 1/20 0.32
HDAC1 Q13547 1/20 0.32
HDAC7 Q8WUI4 1/20 0.32
HDAC2 Q92769 1/20 0.32
HDAC10 Q969S8 1/20 0.32
HDAC11 Q96DB2 1/20 0.32
HDAC8 Q9BY41 1/20 0.32
HDAC6 Q9UBN7 1/20 0.32
HDAC9 Q9UKV0 1/20 0.32
HDAC5 Q9UQL6 1/20 0.32
SOAT2 O75908 1/20 0.32
SOAT1 P35610 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18244699 1.00 SMYD2 (0.33) SMYD2CYP3A4HTTSMN1; SMN2ACLY
SCHEMBL3705314 0.99 SMYD2 (0.34) SMYD2CYP3A4HTTSMN1; SMN2ACLY
SCHEMBL13778516 0.94 SMYD2 (0.34) SMYD2CYP3A4HTTSMN1; SMN2PPARG
SCHEMBL15644378 0.92 TBXAS1 (0.34) SMYD2CYP3A4HTTSMN1; SMN2ACLY
SCHEMBL15644204 0.92 TBXAS1 (0.34) SMYD2CYP3A4HTTSMN1; SMN2ACLY
SCHEMBL15643645 0.92 TBXAS1 (0.34) SMYD2CYP3A4HTTSMN1; SMN2ACLY
SCHEMBL12989467 0.92 TBXAS1 (0.34) SMYD2CYP3A4HTTSMN1; SMN2ACLY
SCHEMBL12989442 0.92 TBXAS1 (0.34) SMYD2CYP3A4HTTSMN1; SMN2ACLY
SCHEMBL25764486 0.92 TBXAS1 (0.34) SMYD2CYP3A4HTTSMN1; SMN2ACLY
SCHEMBL7632423 0.90 SMYD2 (0.34) SMYD2CYP3A4HTTSMN1; SMN2ACLY

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9988349-B2 Direct stereospecific synthesis of unprotected aziridines from olefins NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2018-06-05 US disclosed
US-20160340305-A1 DIRECT STEREOSPECIFIC SYNTHESIS OF UNPROTECTED AZIRIDINES FROM OLEFINS NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2016-11-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160340305-A1 DIRECT STEREOSPECIFIC SYNTHESIS OF UNPROTECTED AZIRIDINES FROM OLEFINS AAAS, NISCH, HNMT SMYD2 2761/4885CYP3A4 172/4885HTT 477/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.